Introduction
Gastrointestinal Injury, small-intestinal injury, cardiovascular disease, GIB
EVENTS, SECONDARY, CARDIOVASCULAR DISEASE
Antiplatelet regimens are widely used for secondary prevention of cardiovascular disease to reduce the risk of recurrent ischemic events after percutaneous coronary intervention (PCI).Despite these considerations, the incidence of gastric and small-intestinal injury progression among patients without high GIB risk has not been well defined. In addition, the effects of different antiplatelet regimens, including aspirin, clopidogrel, or dual antiplatelet therapy (DAPT), on gastric and small-bowel injury progression remain unknown.To explore gastric and small-intestinal injury progression induced by aspirin, clopidogrel, and DAPT in patients without high GIB risk, we conducted a secondary analysis of the Optimal Antiplatelet Therapy for Prevention of Gastrointestinal Injury Evaluated by ANKON Magnetically Controlled Capsule Endoscopy (OPT-PEACE) trial.